Pallas Health Review: The Only Seller That Admits Its Evidence Is Thin

The sentence on the product page

Here is what Pallas says about NAD+, the product it is trying to sell you:

"Research on supplemental NAD+ is still developing — which is why a US-licensed clinician reviews your health history and prescribes it only when it's appropriate for you."

Read that against what the same molecule is sold on elsewhere in this roster. One competitor's page: "NAD+ declines with age. This restores it. Feel like yourself again." Another promises it will "boost your immune system" and "reduce inflammation" and calls it "the ultimate biohack". A third calls NAD+ "a peptide that signals your own pituitary gland", which it is not.

Pallas writes that levels decline with age and that this is "one reason many people explore replenishing it". That sentence describes a motivation rather than asserting a result, and the difference is the whole of what this site exists to notice.

The underlying evidence position is no better than anyone else's. There is no completed randomised trial of injected NAD+ in humans supporting a restoration-of-function claim, and none of intranasal NAD+ at all. ¹ The substantial human literature concerns oral precursors — nicotinamide riboside and nicotinamide mononucleotide — different molecules taken a different way, whose results do not transfer to a spray or an injection.

Pallas does not tell you that last part, and it is the single most useful thing a buyer of this product could be told. But it also does not pretend the evidence is settled, which makes it the only company here whose NAD+ page a reader can trust to be under-claiming rather than over-claiming.

The twelve weeks that are not three months

The defect, and there is really only one of substance.

Every Pallas plan bills on a twelve-week cycle. The site advertises monthly figures derived by dividing by three:

| Product | First period | Then | Advertised | Real year | |---|---|---|---|---| | NAD+ nasal spray | $79 | $567 / 12 weeks | "$189/mo" | $2,457 | | NAD+ injection | $89 | $597 / 12 weeks | "$199/mo" | $2,587 | | Semaglutide | $139 | $597 / 12 weeks | "$199/mo" | $2,587 | | Tirzepatide | $179 | $897 / 12 weeks | "$299/mo" | $3,887 |

Twelve weeks is 2.769 months, not three. And a twelve-week cycle arrives 4.33 times a year, not four — so the year costs about 8.3% more than "$X/mo × 12" implies. On tirzepatide that is roughly $300 a year the monthly figure does not mention.

Two things in Pallas's favour here, because the arithmetic alone would be unfair. It prints the cycle total — "$567 every 12 weeks ($189/mo average)" — where several competitors print only the divided number and leave you to discover the protocol length at checkout. And it labels the figure an "average" rather than a price. The unit is still wrong, and a reader budgeting monthly will still be short, but Pallas has put the true number on the page.

There is no month-to-month rung for the compounded GLP-1s. Twelve weeks is the only commitment on offer.

The footer that disclaims the site

Underneath all of this, on every page:

"Some content on this site is AI-generated; no representation or warranty is made regarding its accuracy, completeness, or reliability."

Pallas publishes 51 state-by-state telehealth guides, a dosing calculator, a BMI calculator, a body-fat calculator, a calorie calculator and a weight-loss projection tool. That sentence disclaims the reliability of all of it.

It is an honest disclosure in one sense — most sites generating content this way say nothing — and a strange one to place under health information a patient might act on. It is the one place where Pallas's instinct for transparency produces something that undermines rather than helps.

A second thing does not reconcile. The homepage advertises "200,000+ patients". The clinical page says the patient portal "goes live alongside our July 2026 launch", refers to "existing waitlist patients", and three of the five product lines on the homepage — MIC + B12, skincare, hormone therapy — are still marked "Coming soon". Those statements can perhaps be squared, but the site does not square them.

What is actually for sale

For a peptide buyer, Pallas's range is thin and worth being clear about.

NAD+ is a coenzyme, not a peptide — a dinucleotide, with no amino-acid chain. Pallas gets this right on the page, calling it "a coenzyme found in every cell", where a competitor in this same wave calls it a peptide.

That leaves the two GLP-1s, semaglutide and tirzepatide, as the only true peptides Pallas sells. Both have genuine phase 3 evidence behind the approved products — STEP 1 and SURMOUNT-1 ^{2 3} — and Pallas makes almost no efficacy claim about either in its own voice: no percentage, no trial named, no transformation promised. There is nothing here to grade as overstatement because there is very little claimed.

MIC + B12 is on a waitlist and is not sold. It is not a peptide either.

What this means if you are buying

If what you want is a company that will tell you who is compounding your medication and how to reach them, Pallas is the best answer in this roster, and it is not a close call. Six named pharmacies with phone numbers, two named doctors with verifiable NPIs, an accurate account of what its regulatory categories mean, and a clear statement that you are not charged if you are turned down.

Budget on the cycle, not the month. The NAD+ injection is $597 every twelve weeks, which is $2,587 a year — not the $2,388 that "$199/mo" suggests. Tirzepatide is $3,887.

And on the product itself, take Pallas at its word rather than at its competitors'. The research on supplemental NAD+ is still developing. What the page leaves out is that the developing research is mostly about oral precursors, not the spray or the injection you would be buying.